Long-term use of clobazam in Lennox-Gastaut syndrome: experience in a single tertiary epilepsy center.

Abstract

OBJECTIVE:

Clobazam (CLB) is a 1,5-benzodiazepine, which is known to be effective for treating refractory partial epilepsy. We have evaluated the long-term efficacy and tolerability of CLB as an add-on therapy in patients with Lennox-Gastaut syndrome (LGS).

METHODS:

Forty-six patients with LGS who had received CLB add-on therapy were enrolled in this study. We retrospectively reviewed their clinical characteristics, including type of seizures, use of CLB, efficacy, adverse events, and retention rate.

RESULTS:

The mean±SD dose of CLB was 0.70±0.37 mg/kg per day (range, 0.16-1.60 mg/kg per day). After 1 month on CLB, 15 patients (32.6%) became seizure-free and 10 patients (21.7%) had 50% or greater seizure reduction. Response to CLB was not significantly associated with age, sex, or etiology (symptomatic or not). Five (10.8%) of 46 patients maintained seizure remission for more than 12 months. Tolerance developed in 48.0% of initial responders, and the 3-year retention rate by the Kaplan-Meier method was 76.6%. Seven patients (15.2%) reported adverse events, including somnolence and behavioral change, but only one discontinued CLB.

CONCLUSIONS:

Clobazam add-on therapy was effective and very tolerable in patients with LGS.

• Authors: Eun Hye Lee, Mi-Sun Yum, Hae-Won Choi, Tae-Sung Ko
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2013 Jan-Feb Vol. 36 Issue 1 Pg. 4-7 ISSN: 1537-162X [Electronic] United States
• PMID: 23334068 (Publication Type: Journal Article)

Chemical References

• Anticonvulsants
• Benzodiazepines
• Clobazam

Topics

• Adolescent
• Anticonvulsants (administration & dosage)
• Benzodiazepines (administration & dosage)
• Child
• Child, Preschool
• Clobazam
• Epilepsy (diagnosis, drug therapy)
• Female
• Humans
• Infant
• Intellectual Disability (diagnosis, drug therapy)
• Lennox Gastaut Syndrome
• Male
• Retrospective Studies
• Spasms, Infantile (diagnosis, drug therapy)
• Tertiary Care Centers (trends)
• Time Factors
• Treatment Outcome
• Young Adult